Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578
Hans@LifeSciAdvisors.com

Recent News

1Oct

CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021

30Aug

CymaBay Therapeutics to Present at Upcoming Investor Conferences

12Aug

CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update

Upcoming Event

Nov 12 2021

The Liver Meeting® 2021

November 12 - November 15, 2021

Virtual

Oral Presentation: November 14th 1:00 PM EST
106: “Long-Term Safety and Efficacy of Seladelpar in Patients with Primary Biliary Cholangitis”

Clinical Poster Presentation: November 12th – 15th
1269: “Efficacy and Safety of Seladelpar in Patients with Compensated Cirrhosis and Evidence of Portal Hypertension due to Primary Biliary Cholangitis”

Preclinical Poster Presentation: November 12th – 15th
1334: “Seladelpar reduces established Liver and Renal Fibrosis in the Non-obese Diabetic Inflammation and Fibrosis (NIF) Mouse Model”

Q2 2021 Quarterly Results